Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORTHO-EST vs MENEST
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Estradiol is a steroid hormone that binds to and activates estrogen receptors (ERα and ERβ), leading to regulation of gene transcription and modulation of various physiological processes including reproductive function, bone metabolism, and cardiovascular health.
Menest is a conjugated estrogens formulation that binds to estrogen receptors (ERα and ERβ), activating genomic signaling pathways that regulate gene transcription. This leads to effects such as proliferation of endometrial and breast tissue, modulation of gonadotropin release, and maintenance of bone density.
Treatment of moderate-to-severe vasomotor symptoms due to menopause,Prevention of postmenopausal osteoporosis,Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,Atrophic vaginitis,Kraurosis vulvae
Moderate to severe vasomotor symptoms associated with menopause,Vulvar and vaginal atrophy,Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,Prevention of postmenopausal osteoporosis (in women at significant risk),Palliative treatment of advanced androgen-dependent carcinoma of the prostate,Palliative treatment of advanced breast cancer in selected postmenopausal women
1.25 mg orally once daily for 21 days, followed by 7 days off; or 0.625 mg orally once daily continuously.
0.625 mg orally once daily for estrogen replacement; dosage range 0.3-1.25 mg daily based on clinical response.
12-18 hours (terminal elimination half-life); clinical context: dosed once daily, steady-state achieved in 5-7 days.
The terminal elimination half-life of conjugated estrogens is approximately 10-24 hours. The half-life of estrone, the primary metabolite, is about 12-18 hours. This supports once-daily dosing.
Primarily hepatic via CYP3A4; undergoes enterohepatic recirculation; metabolites include estrone, estriol, and conjugates.
Conjugated estrogens are metabolized primarily in the liver via hydroxylation and conjugation by cytochrome P450 enzymes (CYP3A4, CYP1A2, CYP2D6) and undergo enterohepatic recirculation.
Renal elimination (90-95%) as glucuronide and sulfate conjugates; fecal (5-10%) via biliary excretion.
Estrogens are excreted primarily in urine (about 90-95%) as glucuronide and sulfate conjugates. The remaining 5-10% is excreted in feces via bile. Less than 5% is excreted unchanged.
50-80% bound to albumin and sex hormone-binding globulin (SHBG); binding to SHBG is approx. 30-50%.
Estrogens are approximately 50-80% bound to serum proteins, primarily sex hormone-binding globulin (SHBG) and albumin. Estrone is about 16% bound to SHBG and 80% to albumin; estradiol has higher SHBG affinity.
1-2 L/kg; clinical meaning: extensive distribution into tissues, including fat and reproductive organs.
The apparent volume of distribution for conjugated estrogens is not well-defined due to tissue binding. For estradiol, Vd is approximately 1.2 L/kg, indicating extensive distribution into tissues and fat.
Oral: 40-60% due to first-pass metabolism; transdermal: approximately 10-20% systemic availability (not primary route).
Oral bioavailability of conjugated estrogens is approximately 40-50% due to first-pass hepatic metabolism. The tablet formulation is designed to deliver a consistent dose; enteric-coated tablets may have slightly different bioavailability.
No dose adjustment required for mild to moderate renal impairment. Severe renal impairment (GFR <30 m L/min): use with caution due to potential accumulation of conjugated estrogens.
No specific dosing adjustment recommended; use with caution in severe renal impairment.
Child-Pugh Class A: no adjustment. Child-Pugh Class B or C: contraindicated due to impaired estrogen metabolism.
Contraindicated in severe hepatic disease (Child-Pugh class C); for mild to moderate impairment (Child-Pugh A or B), use lowest effective dose and monitor liver function.
Not indicated for use in pediatric patients.
Not approved for use in pediatric patients.
Initiate at lowest effective dose (0.625 mg orally once daily) and titrate cautiously due to increased risk of thromboembolic events and endometrial cancer.
Initiate at lowest effective dose (0.3 mg daily) due to increased sensitivity and risk of adverse effects; monitor closely for thromboembolic events and malignancy.
Estrogens increase the risk of endometrial cancer in postmenopausal women with an intact uterus. They should not be used during pregnancy. There is an increased risk of cardiovascular events (e.g., stroke, myocardial infarction) and breast cancer with estrogen-alone therapy.
Estrogens increase the risk of endometrial carcinoma in postmenopausal women. Unopposed estrogen use increases the risk of endometrial hyperplasia and carcinoma. Estrogens should not be used in women with undiagnosed abnormal genital bleeding. Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. Estrogens increase the risk of venous thromboembolism, stroke, and myocardial infarction.
Cardiovascular disorders (thrombophlebitis, thromboembolism), malignancy (breast, endometrial), gallbladder disease, hypercalcemia, fluid retention, hepatic impairment, hypothyroidism, and hereditary angioedema.
Cardiovascular disorders: increased risk of stroke, DVT, pulmonary embolism, and myocardial infarction,Malignant neoplasms: increased risk of endometrial cancer and possibly breast cancer,Gallbladder disease,Hypertriglyceridemia,Fluid retention,Hypocalcemia,Hereditary angioedema,Exacerbation of endometriosis,Visual abnormalities,Dementia risk (when initiated in women >65 years),Jaundice and liver function abnormalities
Known or suspected pregnancy, undiagnosed abnormal genital bleeding, known or suspected breast cancer (except in select cases), known or suspected estrogen-dependent neoplasia, active or history of venous thromboembolism, active or history of arterial thromboembolism, hypersensitivity to estrogens, hepatic impairment or disease, protein C, protein S, or antithrombin deficiency.
Known or suspected pregnancy,Undiagnosed abnormal genital bleeding,Active liver disease or impaired liver function,Known or suspected breast cancer (except in selected metastatic cases),Known or suspected estrogen-dependent neoplasia (e.g., endometrial cancer),Active or history of venous thromboembolism,Active or history of arterial thromboembolism (e.g., stroke, MI),Hypersensitivity to estrogens or any ingredient in Menest
Grapefruit juice may increase systemic exposure to esterified estrogens; avoid concurrent consumption. No other significant food interactions are documented.
Grapefruit and grapefruit juice may increase serum estrogen levels via CYP3A4 inhibition and should be avoided. High-fat meals may increase absorption; take consistently with or without food. Vitamin C supplements may increase estrogen levels.
ORTHO-EST (estradiol) is a pregnancy category X drug. Use is contraindicated during pregnancy. First trimester exposure is associated with a risk of congenital anomalies (e.g., cardiovascular, limb defects, VACTERL association) based on epidemiological data. Second and third trimester exposure may cause fetal harm including urogenital tract abnormalities and potential carcinogenic effects. Estrogens are not recommended for use in pregnancy.
First trimester: Increased risk of congenital anomalies, including cardiovascular and urogenital defects, with non-contraceptive estrogen use. Second and third trimesters: Associated with fetal genital tract abnormalities, increased risk of spontaneous abortion, and preterm delivery. Estrogens are contraindicated in pregnancy.
Estradiol is excreted in human breast milk at low concentrations. The M/P ratio is approximately 0.2–0.3. It may reduce milk production and quality. Use during breastfeeding is generally not recommended, especially in the immediate postpartum period when milk supply is being established. Alternate methods of contraception should be considered.
Estrogens are excreted in human milk in small amounts. M/P ratio not established. Use during breastfeeding is not recommended as it may reduce milk production and affect infant development.
ORTHO-EST is contraindicated in pregnancy. No dose adjustment recommendations exist for use during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) theoretically may require dose adjustment if used, but due to teratogenicity, it should not be used. Postpartum, if estrogen therapy is indicated, consider lower doses due to altered metabolism and risk of thromboembolism.
No dose adjustments recommended; drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy include increased clearance, but no safe dose established.
ORTHO-EST (esterified estrogens) is indicated for moderate to severe vasomotor symptoms due to menopause and for prevention of postmenopausal osteoporosis. It carries a boxed warning for endometrial cancer in women with an intact uterus; co-administration with a progestin is required unless the patient has had a hysterectomy. Risk of venous thromboembolism is increased; avoid in patients with active VTE or history of VTE. Estrogen use may increase risk of breast cancer, especially with prolonged use (>5 years). Do not use in women with undiagnosed abnormal genital bleeding. Monitor for signs of hypercalcemia in patients with metastatic breast cancer or hypoparathyroidism.
Menest (esterified estrogens) contains a mixture of estrogenic substances, primarily sodium estrone sulfate, with lower potency than conjugated equine estrogens (CEE) due to absence of equilin. For vasomotor symptoms, start at lowest effective dose; consider estradiol-based alternatives for better pharmacokinetic profile. Monitor for thromboembolic events; avoid in patients with active liver disease or unexplained vaginal bleeding. Absorption may be impaired in patients with GI malabsorption disorders.
Take ORTHO-EST exactly as prescribed; do not increase dose or frequency without consulting your doctor.,If you have a uterus, you must also take a progestin to protect against endometrial cancer risk.,Report any unusual vaginal bleeding, breast lumps, or changes in discharge promptly.,Avoid smoking while taking estrogen therapy; smoking increases risk of serious cardiovascular events.,Notify your healthcare provider if you develop symptoms of blood clot: sudden leg pain/swelling, chest pain, shortness of breath, or vision changes.,This medication does not prevent pregnancy; use appropriate contraception unless advised otherwise.,Store at room temperature away from moisture and heat.
Take with food or milk to reduce gastrointestinal upset.,Report any sudden severe headache, vision changes, chest pain, or leg swelling immediately.,Avoid grapefruit juice and grapefruit products as they may increase estrogen levels.,Do not smoke while using this medication; smoking increases risk of blood clots and stroke.,Inform your physician of any history of breast cancer, uterine cancer, or blood clotting disorders.,Use the lowest effective dose for the shortest duration possible.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORTHO-EST vs MENEST, answered by our medical review team.
ORTHO-EST is a Estrogen Replacement that works by Estradiol is a steroid hormone that binds to and activates estrogen receptors (ERα and ERβ), leading to regulation of gene transcription and modulation of various physiological processes including reproductive function, bone metabolism, and cardiovascular health.. MENEST is a Estrogen Replacement Therapy that works by Menest is a conjugated estrogens formulation that binds to estrogen receptors (ERα and ERβ), activating genomic signaling pathways that regulate gene transcription. This leads to effects such as proliferation of endometrial and breast tissue, modulation of gonadotropin release, and maintenance of bone density.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORTHO-EST and MENEST depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORTHO-EST is: 1.25 mg orally once daily for 21 days, followed by 7 days off; or 0.625 mg orally once daily continuously.. The standard adult dose of MENEST is: 0.625 mg orally once daily for estrogen replacement; dosage range 0.3-1.25 mg daily based on clinical response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORTHO-EST and MENEST in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORTHO-EST is classified as Category C. ORTHO-EST (estradiol) is a pregnancy category X drug. Use is contraindicated during pregnancy. First trimester exposure is associated with a risk of congenital anomalies (e.g., car. MENEST is classified as Category C. First trimester: Increased risk of congenital anomalies, including cardiovascular and urogenital defects, with non-contraceptive estrogen use. Second and third trimesters: Associat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.